Role of Janus Kinase Inhibitors in Treating Fibrosis in Inflammatory Bowel Disease

Overview

Intestinal fibrosis is a significant complication in inflammatory bowel disease (IBD), particularly Crohn’s disease, with no current anti-fibrotic pharmacological treatments available. Janus kinase (JAK) inhibitors, approved for IBD treatment, show promise not only for their anti-inflammatory effects but also for their potential to interfere with fibrotic processes, suggesting a novel therapeutic avenue for intestinal fibrosis.

Background

Fibrosis in IBD results from excessive extracellular matrix accumulation by fibroblasts, leading to bowel wall stiffening and strictures, especially in Crohn’s disease. Current management of fibrostenotic strictures relies on endoscopic or surgical interventions due to the absence of effective anti-fibrotic drugs. The JAK-STAT signaling pathway, activated by multiple cytokines, regulates inflammation and fibrosis by influencing gene transcription in various cell types, including fibroblasts. JAK inhibitors, which block multiple cytokine pathways, have been approved for IBD and have demonstrated anti-fibrotic effects in other diseases, raising interest in their potential role in intestinal fibrosis.

Data Highlights

Approximately 50% of Crohn’s disease patients develop intestinal fibrosis, while about 5% of ulcerative colitis patients are affected. Endoscopic balloon dilatation is effective in up to 40% of patients with symptomatic strictures but often requires repetition, and 75% eventually need surgery. JAK inhibitors such as filgotinib, upadacitinib, and tofacitinib have been approved for ulcerative colitis, with upadacitinib also approved for Crohn’s disease. Ruxolitinib, a JAK1/2 inhibitor, is approved for myelofibrosis and has shown to impair hepatic stellate cell activation, a key driver of liver fibrosis.

Key Findings

• Intestinal fibrosis affects about half of Crohn’s disease patients and a smaller proportion of ulcerative colitis patients, leading to strictures and bowel dysfunction.
• The JAK-STAT pathway is central to inflammatory and fibrotic signaling in the intestine, activated by multiple cytokines and growth factors.
• JAK inhibitors provide broad anti-inflammatory effects by blocking multiple cytokine pathways simultaneously, unlike biologics targeting single molecules.
• JAK inhibitors have demonstrated anti-fibrotic effects in diseases such as myelofibrosis and liver fibrosis, suggesting potential benefits beyond inflammation control in IBD.
• Current diagnostic methods for intestinal fibrosis lack standardized scoring, complicating clinical development of anti-fibrotic therapies.
• Novel imaging techniques like fibroblast activation protein inhibitor PET/CT are under evaluation to better assess fibrosis severity and distinguish it from active inflammation.

Clinical Implications

JAK inhibitors represent a promising therapeutic option in IBD by targeting both inflammation and potentially fibrosis, which may reduce the need for repeated endoscopic or surgical interventions. Improved diagnostic imaging and standardized fibrosis assessment are essential to evaluate and optimize anti-fibrotic treatment strategies. Clinicians should consider the dual anti-inflammatory and anti-fibrotic potential of JAK inhibitors when managing patients with fibrostenotic Crohn’s disease.

Conclusion

JAK inhibitors offer a novel and multifaceted approach to managing inflammatory bowel disease by addressing both inflammation and fibrosis. Further research and clinical trials are needed to confirm their efficacy in preventing or treating intestinal fibrosis and to integrate these agents into standard care for fibrostenotic IBD.

References

1. Review Article, 2024 -- Exploring the Role of Janus Kinase Inhibitors in Treating Fibrosis Associated with Inflammatory Bowel Disease